HC Wainwright & Co. Reiterates Buy on Viracta Therapeutics, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on Viracta Therapeutics (NASDAQ:VIRX) and maintained a $10 price target.
August 15, 2023 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Viracta Therapeutics and maintained a $10 price target, which could positively impact the stock.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $10 also indicates their confidence in the stock's potential, which could drive buying interest and potentially increase the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100